Application Nr Approved Date Route Status External Links
BLA125118 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Orencia Is A Selective T Cell Costimulation Modulator Indicated For The Treatment Of (1.2, 1.3) : • Adult Patients With Moderately To Severely Active Rheumatoid Arthritis (Ra) • Patients 2 Years Of Age And Older With Moderately To Severely Active Polyarticular Juvenile Idiopathic Arthritis (Pjia) • Adult Patients With Active Psoriatic Arthritis (Psa) Limitations Of Use: Concomitant Use Of Orencia With Other Immunosuppressives [E.g., Biologic Disease-Modifying Antirheumatic Drugs (Bdmards), Janus Kinase (Jak) Inhibitors] Is Not Recommended ( 1.4 , 5.1) . 1.1 Adult Rheumatoid Arthritis Orencia ® Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis. 1.2 Polyarticular Juvenile Idiopathic Arthritis Orencia Is Indicated For The Treatment Of Patients 2 Years Of Age And Older With Moderately To Severely Active Polyarticular Juvenile Idiopathic Arthritis. 1.3 Adult Psoriatic Arthritis Orencia Is Indicated For The Treatment Of Adult Patients With Active Psoriatic Arthritis (Psa). 1.4 Limitations Of Use The Concomitant Use Of Orencia With Other Potent Immunosuppressants [E.g., Biologic Disease-Modifying Antirheumatic Drugs (Bdmards), Janus Kinase (Jak) Inhibitors] Is Not Recommended.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Abatacept

Comments